Condition: Acute Myeloid Leukemia · Sponsor: Huai'an First People's Hospital
This study is a clinical trial aimed at evaluating the efficacy and safety of the VHEA（Venetoclax with Homoharringtonine，Etoposide，Cytarabine）regimen in the treatment of newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) with MLL gene abnormalities. This study includes the induction and consolidation phases of AML treatment.
This description comes directly from the study's public registry record.
Shandong Tao · 15252393900 · TSD8884@126.com
Always discuss trial participation with your own doctor first.
| The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University（Huai'an First People's Hospital） | Huai'an, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06328179